Atrial Fibrillation and Race - A Contemporary Review

Current Cardiovascular Risk Reports

Volumn 7, Issue 5, 2013, Pages 336-345

  Amponsah, Michael K D ^a   Benjamin, Emelia J ^b,c,d   Magnani, Jared W ^b,c  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FRAMINGHAM HEART STUDY   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

African American; Atrial fibrillation; Epidemiology; Ethnicity; Race

Indexed keywords

APIXABAN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DABIGATRAN; RIVAROXABAN; WARFARIN;

CEREBROVASCULAR ACCIDENT; COGNITION; ETHNIC GROUP; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEALTH CARE ACCESS; HEALTH CARE COST; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RHYTHM; HUMAN; MORTALITY; OVERALL SURVIVAL; PREDICTION; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRE; RACE; RACE DIFFERENCE; RADIOFREQUENCY ABLATION; REVIEW; RISK FACTOR; STRATIFICATION; TREATMENT OUTCOME;

EID: 84884190959     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-013-0327-8     Document Type: Review

References (97)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285: 2370-5.
2. • Magnani JW, Rienstra M, Lin H, et al. Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. Circulation. 2011;124: 1982-93. An in-depth review of the epidemiology, genetics and "omics" of atrial fibrillation, with particular emphasis on the contributions of a systems biology approach to AF pathogenesis, risk stratification, and therapies.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22: 983-8.
4. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98: 946-52.
5. Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113: 359-64.
6. • Ball J, Carrington MJ, McMurray JJ, et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013. doi: 10. 1016/j. ijcard. 2012. 12. 093. A contemporary synthesis and systematic review of present studies on the epidemiology and burden of atrial fibrillation.
7. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110: 1042-6.
8. Alonso A, Agarwal SK, Soliman EZ, et al. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2009;158: 111-7.
9. •• Meschia JF, Merrill P, Soliman EZ, et al. Racial disparities in awareness and treatment of atrial fibrillation: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Stroke. 2010;41: 581-7. A large-sized, longitudinal study that demonstrated racial disparities in patient awareness of cardiac conditions and warfarin treatment for AF.
10. Conway DS, Lip GY. Ethnicity in relation to atrial fibrillation and stroke (the West Birmingham Stroke Project). Am J Cardiol. 2003;92: 1476-9.
11. Gunarathne A, Patel JV, Potluri R, et al. Secular trends in the cardiovascular risk profile and mortality of stroke admissions in an inner city, multiethnic population in the United Kingdom (1997-2005). J Hum Hypertens. 2008;22: 18-23.
12. Markus HS, Khan U, Birns J, et al. Differences in stroke subtypes between black and white patients with stroke: the South London Ethnicity and Stroke Study. Circulation. 2007;116: 2157-64.
13. Borzecki AM, Bridgers DK, Liebschutz JM, et al. Racial differences in the prevalence of atrial fibrillation among males. J Natl Med Assoc. 2008;100: 237-45.
14. Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest. 2012;142: 1489-98.
15. Dewhurst MJ, Adams PC, Gray WK, et al. Strikingly low prevalence of atrial fibrillation in elderly Tanzanians. J Am Geriatr Soc. 2012;60: 1135-40.
16. Sliwa K, Carrington MJ, Klug E, et al. Predisposing factors and incidence of newly diagnosed atrial fibrillation in an urban African community: insights from the Heart of Soweto Study. Heart. 2010;96: 1878-82.
17. Zenebe G, Alemayehu M, Asmera J. Characteristics and outcomes of stroke at Tikur Anbessa Teaching Hospital, Ethiopia. Ethiop Med J. 2005;43: 251-9.
18. Nwosu CM, Nwabueze AC, Ikeh VO. Stroke at the prime of life: a study of Nigerian Africans between the ages of 16 and 45 years. East Afr Med J. 1992;69: 384-90.
19. Mu HY, Qiu P, Lu WH, et al. Electrocardiogram Minnesota codings from 30 000 adult cases with Kazakh ethnicity in Xinjiang, China. Zhonghua Liu Xing Bing Xue Za Zhi. 2010;31: 451-4.
20. Kawabata-Yoshihara LA, Bensenor IM, Kawabata VS, et al. Prevalence of electrocardiographic findings in elderly individuals: the Sao Paulo aging & health study. Arq Bras Cardiol. 2009;93(602-7): 51-6.
21. Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4: 313-20.
22. Ringborg A, Nieuwlaat R, Lindgren P, et al. Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace. 2008;10: 403-11.
23. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and Risk Factors for Atrial Fibrillation in Older Adults. Circulation. 1997;96: 2455-61.
24. Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet. 2009;373: 739-45.
25. Jabre P, Roger VL, Murad MH, et al. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. Circulation. 2011;123: 1587-93.
26. Sundquist J, Winkleby MA, Pudaric S. Cardiovascular disease risk factors among older black, Mexican-American, and white women and men: an analysis of NHANES III, 1988-1994. J Am Geriatr Soc. 2001;49: 109-16.
27. Harwell TS, Gohdes D, Moore K, et al. Cardiovascular disease and risk factors in Montana American Indians and non-Indians. Am J Prev Med. 2001;20: 196-201.
28. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity among older adults in the United States, 2007-2010. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. 2013. Available at http://198. 246. 98. 21/nchs/data/databriefs/db106. pdf. Accessed 14 June 2013.
29. Prevalence of coronary heart disease -- United States, 2006--2010. Morbidity and Mortality Weekly Report. Centers for Disease Control and Prevention. 2011;60(40): 1377-1381. Available at http://www. cdc. gov/mmwr/preview/mmwrhtml/mm6040a1. htm?s_cid=mm6040a1_w. Accessed 14 June 2013.
30. Haywood LJ, Ford CE, Crow RS, et al. Atrial fibrillation at baseline and during follow-Up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol. 2009;54: 2023-31.
31. Lipworth L, Okafor H, Mumma MT, et al. Race-specific impact of atrial fibrillation risk factors in blacks and whites in the southern community cohort study. Am J Cardiol. 2012;110: 1637-42.
32. Lau CP, Gbadebo TD, Connolly SJ, et al. Ethnic differences in atrial fibrillation identified using implanted cardiac devices. J Cardiovasc Electrophysiol. 2013;24: 381-7.
33. Selmer C, Olesen JB, Hansen ML, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ. 2012;345: e7895. doi: 10. 1136/bmj. e7895.
34. Kodama S, Saito K, Tanaka S, et al. Alcohol consumption and risk of atrial fibrillation a meta-analysis. J Am Coll Cardiol. 2011;57: 427-36.
35. Gami AS, Hodge DO, Herges RM, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol. 2007;49: 565-71.
36. Magnani JW, Johnson VM, Sullivan LM, et al. P wave duration and risk of longitudinal atrial fibrillation in persons >/= 60 years old (from the Framingham Heart Study). Am J Cardiol. 2011;107: 917-921.
37. Soliman EZ, Prineas RJ, Case LD, et al. Ethnic distribution of ECG predictors of atrial fibrillation and its impact on understanding the ethnic distribution of ischemic stroke in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 2009;40: 1204-11.
38. •• Alonso A, Krijthe BP, Aspelund T, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2: e000102. An AF risk prediction model validated across varied racial groups.
39. Chamberlain AM, Agarwal SK, Folsom AR, et al. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol. 2011;107: 85-91.
40. Hijazi Z, Oldgren J, Siegbahn A, et al. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J. 2013;34(20): 1475-80.
41. Patton KK, Ellinor PT, Heckbert SR, et al. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation. 2009;120: 1768-74.
42. Schnabel RB, Larson MG, Yamamoto JF, et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation. 2010;121: 200-7.
43. Pena JM, MacFadyen J, Glynn RJ, et al. High-sensitivity C-reactive protein, statin therapy, and risks of atrial fibrillation: an exploratory analysis of the JUPITER trial. Eur Heart J. 2012;33: 531-7.
44. Feairheller DL, Park JY, Sturgeon KM, et al. Racial differences in oxidative stress and inflammation: in vitro and in vivo. Clin Transl Sci. 2011;4: 32-7.
45. Cushman M, McClure LA, Howard VJ, et al. Implications of increased C-reactive protein for cardiovascular risk stratification in black and white men and women in the US. Clin Chem. 2009;55: 1627-36.
46. Oyen N, Ranthe MF, Carstensen L, et al. Familial aggregation of lone atrial fibrillation in young persons. J Am Coll Cardiol. 2012;60: 917-21.
47. Lubitz SA, Yin X, Fontes JD, et al. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA. 2010;304: 2263-9.
48. Christophersen IE, Budtz-Jorgensen E, Olesen MS, et al. Familial atrial fibrillation predicts increased risk of mortality: a study in Danish twins. Circ Arrhythm Electrophysiol. 2013;6: 10-5.
49. Yang YQ, Zhang XL, Wang XH, et al. Familial aggregation of lone atrial fibrillation in the Chinese population. Intern Med. 2010;49: 2385-91.
50. Arnar DO, Thorvaldsson S, Manolio TA, et al. Familial aggregation of atrial fibrillation in Iceland. Eur Heart J. 2006;27: 708-12.
51. • Ellinor PT, Lunetta KL, Albert CM, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet. 2012;44: 670-5. A genome-wide association study conducted in cohorts of European ancestry that identified six novel genetic loci for AF, four of which were replicated in Japanese cohorts.
52. Zaitlen N, Pasaniuc B, Gur T, et al. Leveraging genetic variability across populations for the identification of causal variants. Am J Hum Genet. 2010;86: 23-33.
53. Caglayan AO. Different aspects of atrial fibrillation genetics. Interact Cardiovasc Thorac Surg. 2010;11: 779-83.
54. Marcus GM, Alonso A, Peralta CA, et al. European ancestry as a risk factor for atrial fibrillation in African Americans. Circulation. 2010;122: 2009-15.
55. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36: 1115-9.
56. Elijovich L, Josephson SA, Fung GL, et al. Intermittent atrial fibrillation may account for a large proportion of otherwise cryptogenic stroke: a study of 30-day cardiac event monitors. J Stroke Cerebrovasc Dis. 2009;18: 185-9.
57. Kurian AK, Cardarelli KM. Racial and ethnic differences in cardiovascular disease risk factors: a systematic review. Ethn Dis. 2007;17: 143-52.
58. Mathur R, Pollara E, Hull S, et al. Ethnicity and stroke risk in patients with atrial fibrillation. Heart. 2013;99: 1087-92.
59. Members WG, Roger VL, Go AS, et al. Heart Disease and Stroke Statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125: e2-e220.
60. Jones MR, Horner RD, Edwards LJ, et al. Racial variation in initial stroke severity. Stroke. 2000;31: 563-7.
61. Simpson JR, Zahuranec DB, Lisabeth LD, et al. Mexican Americans with atrial fibrillation have more recurrent strokes than do non-Hispanic whites. Stroke. 2010;41: 2132-6.
62. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5): 293-302.
63. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316(23): 1429-35.
64. Shinbane JS, Wood MA, Jensen DN, et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29: 709-15.
65. Gupta DK, Shah AM, Castagno D, et al. Heart failure with preserved ejection fraction in African-Americans - the Atherosclerosis Risk in Communities (ARIC) Study. JACC Heart Fail. 2013;1: 156-63.
66. •• Chen LY, Sotoodehnia N, Bůžková P, et al. Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. JAMA Intern Med. 2013;173: 29-35. This study demonstrated the association between AF and sudden cardiac death.
67. Ott A, Breteler MMB, de Bruyne MC, et al. Atrial fibrillation and dementia in a population-based study: the Rotterdam study. Stroke. 1997;28: 316-21.
68. Marzona I, O'Donnell M, Teo K, et al. Increased risk of cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and TRANSCEND studies. CMAJ. 2012;184: E329-36.
69. Hawkins LA, Kilian S, Firek A, et al. Cognitive impairment and medication adherence in outpatients with heart failure. Heart Lung. 2012;41: 572-82.
70. Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol. 2000;36: 1303-9.
71. Jenkins LS, Brodsky M, Schron E, et al. Quality of life in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005;149: 112-20.
72. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131: 492-501.
73. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154: 1449-57.
74. Dang MT, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother. 2005;39: 1008-12.
75. Shen AY-J, Chen W, Yao JF, et al. Effect of race/ethnicity on the efficacy of warfarin: potential Implications for prevention of stroke in patients with Atrial Fibrillation. CNS Drugs. 2008;22: 815-26.
76. Shen AY-J, Yao JF, Brar SS, et al. Racial/ethnic differences in ischemic stroke rates and the efficacy of warfarin among patients with atrial fibrillation. Stroke. 2008;39: 2736-43.
77. Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37: 1070-4.
78. •• Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013. doi: 10. 1016/S0140-6736(13)60681-9. A GWAS of African-Americans that discovered a novel single nucleotide polymoprmism affecting warfarin metabolism.
79. Ibrahim SA, Kwoh CK, Harper DL, et al. Racial differences in the utilization of oral anticoagulant therapy in heart failure: a study of elderly hospitalized patients. J Gen Intern Med. 2000;15: 134-7.
80. Schwamm LH, Reeves MJ, Pan W, et al. Race/ethnicity, quality of care, and outcomes in ischemic stroke. Circulation. 2010;121: 1492-501.
81. Christian JB, Lapane KL, Toppa RS. Racial disparities in receipt of secondary stroke prevention agents among US nursing home residents. Stroke. 2003;34: 2693-7.
82. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in patients with atrial fibrillation. New Engl J Med. 2009;361: 1139-51.
83. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2011;365: 981-92.
84. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation. New Engl J Med. 2011;365: 883-91.
85. Bush D, Martin LW, Leman R, et al. Atrial fibrillation among African Americans, Hispanics and Caucasians: clinical features and outcomes from the AFFIRM trial. J Natl Med Assoc. 2006;98: 330-9.
86. van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362: 1363-73.
87. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005;293: 2634-40.
88. United States. Agency for Healthcare R, Quality. National healthcare disparities report 2010. 2011. Available at http://www. ahrq. gov/research/findings/nhqrdr/nhqrdr10/qrdr10. html. Accessed 1 July 2013.
89. Orsi JM, Margellos-Anast H, Whitman S. Black-White health disparities in the United States and Chicago: a 15-year progress analysis. Am J Public Health. 2010;100: 349-56.
90. Frey WH. America Reaches Its Demographic Tipping Point. Available at http://www. brookings. edu/blogs/up-front/posts/2011/08/26-census-race-frey. Accessed July 1, 2013.
91. Thomas J, Thomas DJ, Pearson T, et al. Cardiovascular disease in African American and white physicians: the Meharry Cohort and Meharry-Hopkins Cohort Studies. J Health Care Poor Underserved. 1997;8: 270-83. discussion 84.
92. Zhang T, Tsang W, Wijeysundera HC, et al. Reporting and representation of ethnic minorities in cardiovascular trials: a systematic review. Am Heart J. 2013;166: 52-7.
93. Katz RV, Green BL, Kressin NR, et al. Willingness of minorities to participate in biomedical studies: confirmatory findings from a follow-up study using the Tuskegee Legacy Project Questionnaire. J Natl Med Assoc. 2007;99: 1052-60.
94. Bell M, Lommel T, Fischer JG, et al. Improved recognition of heart attack and stroke symptoms after a community-based intervention for older adults, Georgia, 2006-2007. Prev Chronic Dis. 2009;6: A41.
95. Mbewu A, Mbanya JC. Cardiovascular Disease. In: Jamison DT, Feachem RG, Makgoba MW, et al., editors. Disease and mortality in sub-Saharan Africa. Washington DC: The International Bank for Reconstruction and Development/The World Bank; 2006.
96. Deswal A, Petersen NJ, Urbauer DL, et al. Racial variations in quality of care and outcomes in an ambulatory heart failure cohort. Am Heart J. 2006;152: 348-54.
97. Quinn SC. Ethics in public health research: protecting human subjects: the role of community advisory boards. Am J Public Health. 2004;94: 918-22.